19 Indian companies sign licensing pact for Pfizer's oral Covid drug

Torrent Pharma and Cadila Pharma sign licensing agreement with MPP to make and market the drug

The Medicines Patent Pool (MPP) announced on Thursday that it has signed agreements with 35 companies to manufacture the generic version of Pfizer’s oral Covid-19 treatment nirmatrelvir, which in combination with a low dose of ritonavir can be supplied in 95 low- and middle-income countries.
 

This includes 19 Indian drug makers like Torrent Pharma, Cadila Pharma, Hetero, Biocon, Strides, Glenmark, Emcure, Granules, Macleods, Sun Phar­ma, and Cipla among others.
 

MPP is an UN-based public health organisation working to increase access to life-saving medicines for low and middle-income countries (LMICs). MPP has an agreement with PF Prism Holdings BV (Pfizer) that